Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 26:9:F1000 Faculty Rev-1049.
doi: 10.12688/f1000research.26083.1. eCollection 2020.

The most recent advances in understanding and managing hidradenitis suppurativa

Shanthi Narla  1 , Alexis B Lyons  1 , Iltefat H Hamzavi  1
Affiliations
Review

The most recent advances in understanding and managing hidradenitis suppurativa

Shanthi Narla et al. F1000Res. .

Abstract

Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. HS has a significant negative impact on both the quality of life (QOL) of patients affected by this disease as well as family members and caregivers. However, the pathogenesis of HS is multifactorial and still remains to be fully elucidated, which makes the development of treatments difficult. The last 10 years have seen a surge in HS research, and many new findings have come to light, yet much more remains to be elucidated. Physicians must employ a multidisciplinary approach to maximally address all facets of HS. Clinical characteristics of the disease that differ between females and males as well as across different races and ethnic groups must be considered. Targeted topical, oral, and injectable therapies continue to be developed for HS as a greater understanding of the pathogenesis is reached. However, randomized controlled trials regarding dietary factors that may contribute to HS are needed to meet our patients' growing concerns and questions about the role of diet in HS pathogenesis. Finally, improved outcome measures are needed to standardize HS severity and grading between physicians and clinical trials, and a more diverse representation of HS populations is needed in clinical trials.

Keywords: COVID-19; Hidradenitis suppurativa; adalimumab; complementary and alternative medicine; diet; fibroblasts; guidelines; historic; immunomodulatory therapies; international; multidisciplinary; outcome measures; pregnancy; skin of color; theseus; tunnels.

PubMed Disclaimer

Conflict of interest statement

Competing interests: IHH is on the advisory board for AbbVie, is a principal investigator for Ferndale Laboratory, Inc., Galderma Laboratories, Inc., Janssen Biotech, Pfizer Inc., Bayer, Unigen Inc., Allergan, Johnson & Johnson, and Incyte, is president of the HS foundation, and is a sub-investigator for Bristol-Myers Squibb and for Merck/MK-3200-011. SN is a sub-investigator for Pfizer, L’Oréal, Incyte, Lenicura, and Biofrontera. ABL is a sub-investigator for Incyte, Beiersdorf, Unigen Inc., General Electric, Lenicura, Estee Lauder, Miragen, Biofrontera, Pfizer, and L’Oréal.No competing interests were disclosed.No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. A multidisciplinary approach to hidradenitis suppurativa.
See this image and copyright information in PMC

References

    1. Alikhan A, Sayed C, Alavi A, et al. : North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76–90. 10.1016/j.jaad.2019.02.067 - DOI - PMC - PubMed
    1. Marasca C, Napolitano M, Monfrecola G, et al. : Quality of life in people living with patients suffering from hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020;34(7):e342–e343. 10.1111/jdv.16319 - DOI - PubMed
    1. Kimball AB, Crowley JJ, Papp K, et al. : Baseline patient-reported outcomes from UNITE: An observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice. J Eur Acad Dermatol Venereol. 2020;34(6):1302–8. 10.1111/jdv.16132 - DOI - PMC - PubMed
    1. Sampogna F, Fania L, Mazzanti C, et al. : The impact of hidradenitis suppurativa on general health is higher than that of hypertension, congestive heart failure, type 2 diabetes, myocardial infarction and depression. J Eur Acad Dermatol Venereol. 2020;34(8):e386–e388. 10.1111/jdv.16290 - DOI - PubMed

    2. Faculty Opinions Recommendation

    1. Jørgensen AHR, Holm JG, Ghazanfar MN, et al. : Factors affecting quality of life in patients with hidradenitis suppurativa. Arch Dermatol Res. 2020;312(6):427–36. 10.1007/s00403-019-02025-5 - DOI - PubMed

    2. Faculty Opinions Recommendation